[1] HUANG B, XU C, LI G, et al. Effects of Daphne genkwa on the intestinal transport absorption of rhodamine 123. Chin Pharm J(中国药学杂志), 2010, 45(1):23-27. [2] MARZOLINI C, PAUS E, BUCLIN T, et al. Polymorphisms in human MDR1(P-glycoprotein):Recent advances and clinical relevance. Clin Pharmacol Ther, 2004, 75(1):13-33. [3] FROMM M F, KIM R B. Drug Transporters, Handbook of Experimental Pharmacology 201. Berlin Springer Verlag Berlin Heideberg, 2011:261-283. [4] SRINIVAS N R, RAMESH M. Digoxin - a therapeutic agent and mechanistic probe:Review of liquid chromatographic mass spectrometric methods and recent nuances in the clinical pharm-cology attributes of digoxin. Bioanalysis, 2009, 1(1):97-113. [5] MITAMURA K, HORIKAWA A, YAMANE Y, et al. Determination of digoxin in human se rum using stable isotope dilution liquid chromatography/electrospray ionization-tandem mass spectrometry. Biol Pharm Bull, 2007, 30(9):1653-1656. [6] PU X, ZHAO H, LI H. Aplication and progression of biopharmaceutical analyzing methods of digoxin. J Shenyang Pharm Univ(沈阳药科大学学报), 2006, 23(7):471-476. [7] YAO M, ZHANG H, CHONG S, et al. A rapid and sensitive LC/MS/MS assay for quan- titative determination of digoxin in rat plasma. J Pharm Bio Ana, 2003, 32(6):1187-1197. [8] STOLL R G, CHRISTENSENH M S, SAKMAR E, et al. The specificity of the digoxin radio-immunoassay procedure. Res Commun Chem Pathol Pharmacol, 1972, 4(3):503-510. [9] TRACQUI A, KINTZ P, LUDES B, et al. High-performance liquid chromatography mass spectrome-trometry for the specific determination of digoxin and some related cardiac glycosides in hu-man plasma. J Chromtogr B Biomed Sci, 1997, 692(1):101-109. KIRBY B J, KALBORN T, UNADKAT J D, et al. Sensitive and specific LC-MS assay for quantification of digoxin in human plasma and urine. Biomed Chromatogr, 2008, 22(7):712-718. XUE X, HUANG M, XIAO H, et al. Rapid and simultaneous measurement of midazolam, 1′- hydroxymidazolam and digoxin by liquid chromatography/tandem mass spectrometry:Appli-cation to an in vivo study to simultaneously measure P-glycoprotein and Cytochrome P450 3A activity. J Pharm Biomed Anal, 2011, 55(1):187-193. SMALLEY J, MARINO A M, XIN B, et al. Development of a quantitative LC-MS/MS analy-tical method coupled with turbulent flow chromatography for digoxin for the in vitro P-gp inhibition assay. J Chromatogr B Analyt Technol Biomed Life Sci, 2003, 854(1-2):260-267. MITAMURA K, HORIKAWA A, YAMANE Y, et al. Determination of digoxin in human serum using stable isotope dilution liquid chromatography/electrospray ionization tandem mass spectrometry. Biol Pharm Bull, 2007, 30(9):1653-1656. HASHIMOTO Y, SHIBAKAWA K, NAKADE S, et al. Validation and application of a 96- well fomat solid-phase extraction and liquid chromatography-tandem mass spectrometry method for the quantitation of digoxin in human plasma. J Chromatogr B, 2008, 869(1-2):126-132. HIRABAYASHI H, SUGIMOTO H, MATSUMOTO S, et al. Development of a quantification method for digoxin, a typical P-glycoprotein probe in clinical and non-clinical studies, using high performance liguid chromatography-tandem mass spectrometry:The usefulness of negative ionization mode to avoid competitive adduct-ion formation. J Chromtogr B, 2011,879(32):3837-3844. LI Y, SHIRASAKA Y, LANGGUTH P, et al. Quantitation of talinolol in rat plasma by LC-MS-MS. J Chromatogr Sci, 2010, 48(5):367-370. HAN Y, GUO D, ZHOU H H, et al. Effect of continuous silyarin administration on oral talinolol pharmacokinetics in healthy volunteers. Xenobiotica, 2009, 39(09):649-699. ZHOU Z J. Study on the pharmacokinetics of talinolol tablets in healthy volunteers with HPLC-MS/MS assay. Qilu Pharm Affairs(齐鲁药事), 2009, 28(1):38-41. ZHAO R K, CAO J H, PENG W X, et al. Effect of duloxetine on the pharmacokinetics of talinol in humans. Central South Pharm(中南药学), 2011, 9(6):430-433. HE J, BERND T, YANG L Y, et al. Determination of talinolol in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry:Application to pharmacokinetic study. J Chromatogr B, 2007, 853(1-2):275-80. SIGH S P, WAHAJUDDIN, ALI M M, et al. Liquid chromatography-mass spectrometry method for the quantification of tamoxifen and its metabolite 4-hydroxytamoxifen in rat plasma:Application to interaction study with biochanin A(an isoflavone). J Chromatogr B, 2011, 879(27):2845-2851. MA R H, WEN X D, LI P, et al. In vivo microdialysis with LC-MS for analysis of spinosin and its interaction with cyclosporin A in rat brain, blood and bile. J Pharm Biome Ana, 2012,61(1):22-29. LAN K, HE J, TIAN Y, et al. Intra-herb pharmacokinetics interaction between quercetin and I sorhamentin. Acta Pharmacol Sin, 2008, 29(11):1376-1382. PAEK I B, JI H Y, KIM M S, et al. Simultaneous determination of paclitaxel and a new P-glycoprotein inhibitor HM-30181 in rat plasma by liquid chromatography with tandem mass spectrometry. J Sep Sci, 2006, 29(5):628-634. SAKUGAWA T, MIURA M, HOKAMA N, et al. Enantioselective disposition of fexofena-dine with the P-glycoprotein inhibitor verapamil. Br J Clin Pharmacol, 2009, 67(5):535-540. HE Y, LIU Y, ZENG S. Stereoselective and multiple carrier-mediated transport of cetirizine across caco-2 cell monolayers with potential drug interaction. Chirality, 2010, 22(7):684-692. YANG E, WANG S, KRATZ J, et al. Stereoselective analysis of carvedilol in human plasma using HPLC-MS/MS after chiral derivatization. J Pharm Bio Analysis, 2004, 36(3):609-615. XIAO T L, ARMSTRONG D W. Chiral Separations. Humana Press, NJ,USA, 2004:113. KINGBACK M, JOSEFSSON M, KARLSSON L, et al. Stereoselective determination of venlafaxine and tis thre demethylated metabolites in human plasma and whole blood by liquid chromatography with electrospray tandem mass spectrometric detection and solid phase extraction. J Pharm Biomed Anal, 2010, 53(3):583-590. KARLSSON L, SCHMITT U, JOSEFSSON M, et al. Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. Euro Neu-ropsychopharm, 2010, 20(9):632-640.